ArticleScientific reports2025
Proteomics analysis reveals progesterone receptor induced mitochondria-mediated apoptosis in breast cancer cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ligand-Dependent and -Independent Functions of Activation Function 1 of Progesterone Receptor in Genome-Wide Gene Regulation and in Cell Proliferation and Apoptosis of Breast Cancer Cells.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The progesterone receptor (PR) expression is associated with disease-free survival in breast cancer. Yet, PR is known to elicit the activation of pro-tumor or anti-tumor signalling pathways. To gain a comprehensive understanding of intrinsic activities of PR, we conducted a global profiling of PR-regulated proteins using Tandem Mass Tag (TMT) proteomics in MCF-7 cells with elevated PR levels. The analysis identified reliably and reproducibly 4,915 PR-regulated proteins and 678 phosphorylated peptides in response to progestin R5020. Consistent with its growth inhibitory activity, PR broadly reduced levels of proteins for cell division, including CDKs, cyclins, DNA replication factors, and proteins involved in chromatin condensation, spindle assembly and chromosome segregation. PR also induced previously reported upregulation of pro-growth proteins such as EGFR, IRS2, and CCND1, but the upregulations are functionally futile due partly to inhibitory phosphorylation. Importantly, PR regulated 200 mitochondrial proteins including proapoptotic factors BNIP3, NIX, AIF/AIFM1, AIFM2, ENDOG, HtrA2/Omi, and Smac/DIABLO, culminating in mitochondria-mediated apoptosis independent of caspases. In conclusion, this proteomics study achieved to date the most comprehensive understanding of PR-regulated molecular networks that are strongly anti-proliferative and proapoptotic with pivotal involvement of mitochondria. PR agonists warrant evaluation for the treatment of breast cancer with high PR expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.